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Brains from patients with Parkinson disease or dementia
with Lewy bodies show aggregation of alpha-synuclein
in precerebellar brainstem structures. Furthermore,
patients exhibit resting tremor, unstable gait, and
impaired balance, which may be associated with cere-
bellar dysfunction. Therefore, we screened the cerebella
of 12 patients with alpha-synucleinopathies for neuro-
pathological changes. Cerebellar nuclei and neighboring
white matter displayed numerous aggregates, whereas
lobules were mildly affected. Cerebellar aggregation
pathology may suggest a prionlike spread originating
from affected precerebellar structures, and the high
homogeneity between patients with dementia with
Lewy bodies and Parkinson disease shows that both dis-
eases likely belong to the same neuropathological
spectrum.
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Parkinson disease (PD) and dementia with Lewy bodies(DLB) belong to the human alpha-synucleinopathies,
which are characterized by neurodegeneration and wide-
spread aggregation of the alpha-synuclein protein.1–3 They
were originally described as different diseases, but are
more recently considered to represent different clinical pat-
terns within the same clinicopathological spectrum.4,5
The disease symptoms of PD include rigidity, brady-
kinesia, gait and postural instability, resting tremor,
impaired balance and postural reflexes, and a pronounced
L-dopa responsiveness of the cardinal motor symptoms, as
well as the manifestation of nonmotor symptoms includ-
ing autonomic, sleep, sensory, gastrointestinal, oculomo-
tor, and mood disturbances.6,7 In the advanced disease
stages 25 to 40% of all PD patients display a dementing
syndrome, usually referred to as PD with dementia
(PDD).7 Most PD cases are idiopathic, although there are
familial forms, several of which are monogenic and have a
brain neuropathology more or less identical to that of
idiopathic PD, for example, the alanine to proline (A30P)
mutation of the alpha-synuclein protein.6,8
DLB represents the second most common dementing
neurodegenerative disorder.3,9 The clinical manifestations
include cardinal symptoms, that is, progressive and fluctuat-
ing dementia, recurrent visual hallucinations, and
Parkinson-like motor manifestations and secondary symp-
toms (ie, autonomic, sleep, dysphagia, and oculomotor
symptoms, depression, and executive dysfunction).3 As with
PD, DLB cases are usually idiopathic, although several
familial forms including monogenic causes are known.10
In the brains of PD and DLB patients, the follow-
ing alpha-synuclein–immunopositive, insoluble aggregates
occur: (1) Lewy bodies (LB) in the neuronal perikarya;
(2) Lewy neurites (LN) in neuronal processes; (3) coiled
bodies (CB) in oligodendrocytes.3,11–13 The PD-related
brain pathology presumably propagates along neuronal
interconnectivities in a prionlike manner and spreads in
highly stereotypical temporal and topographical sequen-
ces, which were compiled into a neuropathological stag-
ing system by Braak et al.2,14 Because DLB patients
exhibit similar brain distribution patterns of aggregation
pathology as PD patients, it is tempting to suggest that
analogous mechanisms of propagation are at work.12,15,16
Several of the motor symptoms of PD and DLB
patients (ie, resting tremor, disturbed balance, gait and
postural reflexes), do not respond well to the widely used
L-dopa treatment but can be associated with pathological
changes in pre- or postcerebellar circuits or the cerebel-
lum itself, which was considered to be unaffected by the
aggregation pathology in PD and DLB.2,17,18 Addition-
ally, recent systematic studies demonstrated cerebellar
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pathology in a monogenic PD patient with the A30P
mutation as well as alpha-synuclein aggregates in precere-
bellar brainstem structures in idiopathic PD and DLB
patients.8,12 This implies a distinct possibility that the
cerebellum is affected by the aggregation pathology in
idiopathic PD and DLB. Thus, we performed a system-
atic investigation of the neuropathology of the cerebella
of PD and DLB patients and a reinvestigation of the cer-
ebellum of a patient with the A30P mutation.
Patients and Methods
Patients
We examined the cerebella of 5 PD, 1 PDD, and 5 DLB
patients as well as the cerebellum from a patient with the A30P
mutation and 4 control cases (Supplementary Table 1).8 The
study was approved by the Ethics Committee of the Faculty of
Medicine at the Goethe University of Frankfurt am Main.
Immunohistochemical Procedures
The cerebella were fixed in 4% aqueous formalin, embedded in
polyethylene glycol (PEG 1000; Merck, Darmstadt, Germany),
and cut into sets of 100lm-thick serial sagittal sections.
To assess neurodegeneration, 1 set of sections was treated
with aldehyde-fuchsin and Darrow red (pigment-Nissl staining).
To visualize alpha-synuclein aggregation, a second set was
immunostained with the monoclonal syn-1 antibody (catalog
number 610786, 1:2,000; BD Biosciences, San Jose, CA),
which targets amino acid 91–99 of rat alpha-synuclein
(ATGFVKKDQ), a sequence that is 100% homologous to
human alpha-synuclein.12
The severity of neuronal and oligodendroglial aggrega-
tion pathology in representative tissue sections through the
deep cerebellar nuclei, the surrounding white matter, and the
cerebellar lobules was scored as absent (0, cerebellar compo-
nent devoid of aggregates), mild (1, cerebellar component
with scarce aggregates), marked (2, cerebellar component with
numerous aggregates), or severe (3, cerebellar component
filled with aggregates). Medians were calculated for each area
of interest. Neurodegenerative changes were evaluated by
comparing pigment-Nissl–stained sections to matching control
sections.
The nonparametric Friedman test was performed to doc-
ument the reliability of our assessments, whenever >1 section
was available for a given area of interest. We additionally con-
firmed our semiquantitative assessment of neurodegenerative
changes by comparing the neuronal densities of 10 randomly
chosen fields of vision within an area of interest between
patient and control cerebella with the 2-sample t test. All evalu-
ations were performed using BIAS software for Windows.
FIGURE 1: Types of cerebellar alpha-synuclein aggregates encountered in Parkinson disease and dementia with Lewy bodies.
(A) A classical Lewy neurite (arrows) in the cerebellar white matter. (B) An ovoid Lewy neurite (arrows) in the white matter of a
cerebellar lobule bordering on the granule cell layer (GCL). (C) A rare Lewy body (arrow) within a neuron of the fastigial
nucleus. (D) Oligodendroglial coiled bodies (arrowhead) are frequently encountered within areas with marked or severe white
matter pathology. (A–D: mouse anti–alpha-synuclein; 100lm thick, polyethylene glycol–embedded sections.) [Color figure can
be viewed at www.annalsofneurology.org]
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FIGURE 2: Alpha-synuclein aggregation in different cerebellar areas. (A) A meshwork of Lewy neurites in the dentate nucleus
(arrows, insert), which is bordered by mostly unaffected areas (asterisks). (B, C) Marked alpha-synuclein pathology in the embo-
liform and fastigial nuclei, respectively (arrows). (D) Severe alpha-synuclein pathology in the pars cerebellaris locus coerulei
(arrows). (E) A single affected branching neuron (arrows) within the otherwise unstained granular cell layer (asterisk). (F)
Marked neuritic alpha-synuclein pathology (arrows) in the white matter of a cerebellar lobule, with mostly unstained neighbor-
ing granular layer regions (asterisks). (G, H) Severe alpha-synuclein pathology (arrows), including several coiled bodies (arrow-
heads) in the white matter surrounding the deep cerebellar gray matter. (A–H: mouse anti–alpha-synuclein; 100lm thick,
polyethylene glycol–embedded sections.). [Color figure can be viewed at www.annalsofneurology.org]
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TABLE 1. Severity of Aggregation Pathology Scored Separately for LP and Frequency of CB










LP 2 1 2 1 1 2 1 (0–2)
CB 1 (0–1) 0 0 0 1 1 0 (0–1)
2
LP 2 1 2 (1–2) 2 2 3 1 (1–2)
CB 1 0 (0–1) 1 0 1 2 0 (0–1)
3
LP 2 2 2 2 2 3 (2–3) 1.5 (1–2)
CB 2 (1–2) 1 1 1 1 1 1 (0–2)
4
LP 2 (1–2) 0.5 (0–1) 1 1 2 2 1 (1–2)
CB 1 0.5 (0–1) 0 0 0 1 0 (0–1)
5
LP 2 (1–2) 1 1 / 1 / 1 (1–2)
CB 2 (1–2) 1 0 / 1 (0–1) / 0 (0–1)
6
LP 2 1 2 2 2 3 1 (1–2)
CB 2 1 2 1 1 1 1 (0–2)
7
LP 2 (2–3) 2 2 2 2 3 2 (2–3)
CB 2 1 1 1 1 1 2 (1–2)
8
LP 2 (1–2) 2 1 1.5 (1–2) 1 2 1 (0–2)
CB 1 (0–1) 0.5 (0–1) 0.5 (0–1) 0.5 (0–1) 0 0 0 (0–1)
9
LP 2 1 1 2 2 3 (2–3) 2 (1–2)
CB 1 (1–2) 1 1 1 1 1 1 (0–2)
10
LP 2 2 2 2 2 3 1 (1–2)
CB 1 1 0.5 (0–1) 1 1 1 0 (0–1)
11
LP 3 / 1.5 (1–2) 2 2 3 (2–3) 2 (1–3)
CB 2 / 1 1 1 1 (1–2) 0 (0–2)
12
LP 2 (2–3) 1.5 (1–2) 1 2 2 3 2 (1–2)
CB 1 (1–2) 1 0 1 1 1 0 (0–1)
Areas investigated are: deep white matter; fastigial, globose, emboliform, and dentate nuclei; PCLC; and cerebellar lobules. The severities are scored
as 0, unaffected; 1, mildly affected; 2, moderately affected; 3, severely affected. / 5 Section unavailable. When cerebellar areas were assessed in >1
slide in a single patient and for all cerebellar lobules, medians and ranges are denoted.
CB 5 coiled bodies; LP 5 Lewy body/neurite pathology; PCLC 5 pars cerebellaris locus coerulei.
Results
The cerebella of all patients displayed neuronal and oligo-
dendroglial alpha-synuclein aggregation pathology, with no
significant differences of severity between the disease
groups (Fig 1). The neuronal aggregation pathology con-
sisted predominantly of LN, whereas LB were significantly
rarer (Fig 2). Alpha-synuclein–immunopositive oligoden-
droglial inclusions were frequently present at cerebellar
sites with at least marked neuronal aggregation pathology
(see Fig 2, Table). No alpha-synuclein–immunopositive
aggregates were detectable in control cerebella.
The central cerebellar nuclei (ie, fastigial, globose,
emboliform, and dentate nuclei) exhibited mild to
marked aggregation pathology, showing mostly LN in
associated neurites and a few LB (see Fig 2, Table). The
pars cerebellaris locus coerulei (PCLC) consistently dis-
played marked aggregation pathology, with an abundance
of LN, LB, and CB that was comparable to the brain-
stem portion of the locus coeruleus.12,19
The deep cerebellar white matter exhibited severe
aggregation pathology. It consisted almost exclusively of
elongated or ovoid LN, located adjacent to the cerebellar
peduncles, in the deep cerebellar nuclei, and in the neu-
ropil neighboring the PCLC (see Fig 2). The neuronal
protein aggregates were frequently accompanied by
alpha-synuclein–immunopositive CB.
The cerebellar cortex showed only minor involve-
ment (see Table 1, Supplementary Table 2). In the
molecular, Purkinje, and granular cell layers, alpha-
synuclein–immunopositive aggregates occurred only occa-
sionally, whereas they were more frequent in the lobular
white matter tracts.
The Friedman test showed a significant difference
between sections in only 1 of 38 investigated groupings.
There was no statistically significant difference between
the aggregation pathology of PD and DLB cases. The
cerebella showed no visible neurodegeneration, with no
significant differences in neuronal density between
matching controls (Patients 15 and 16) and patients.
Discussion
For a long time, the cerebellum was considered to be unaf-
fected in the synucleinopathies PD and DLB, and was not
incorporated in the Braak staging model.2,3,17 However, the
inclusion pathology of precerebellar brainstem nuclei and
fiber tracts points to a possible involvement of the cerebel-
lum in the alpha-synuclein aggregation pathology.12,17 In the
present study, we could for the first time demonstrate the
consistent presence of alpha-synuclein–immunopositive neu-
ronal and oligodendroglial inclusions as a pathological alter-
ation in the cerebellum of idiopathic PD and DLB patients,
with moderate to severe aggregation pathology at the deep
cerebellar nuclei and neighboring white matter tracts and a
milder involvement of the lobules. This new discovery of
cerebellar inclusion pathology was facilitated by the use of
100lm-thick PEG-embedded tissue sections, which, due to
the superposition of neuroanatomical structures, allowed the
recognition of rare alpha-synuclein aggregations (eg, in the
cerebellar lobules). The highly similar distribution of this
cerebellar pathology in both patient groups studied under-
scores that PD and DLB not only share many clinical symp-
toms, but are also neuropathologically indistinguishable in
advanced disease stages and actually represent different
points on the same clinicopathological spectrum.4,5
Currently it is widely held that the alpha-synuclein
pathology of PD and DLB propagates transneuronally along
neuroanatomical connections in a prionlike manner.14,20
This concept is supported by: (1) the typical distribution
pattern of the PD-related inclusion pathology, (2) experi-
mental disease models demonstrating neuron-to-neuron
transmission of pathologically altered alpha-synuclein, and
(3) the invasion of neuronal grafts in PD patients by the
aggregation pathology. Our own findings, together with the
known involvement of precerebellar brainstem nuclei and
the ventrolateral thalamic nucleus, which receives projections
from the cerebellum, support this notion.12
The clinical manifestation of tremor, gait impair-
ment, and postural instability, and the weak response of
these symptoms to L-dopa therapy, suggest that these
symptoms are not primarily caused by the involvement of
the basal gangliothalamocortical loop.17,18 Although the
demonstrated aggregation pathology was only moderate,
and co-occurring neurodegeneration was not discernable,
the hypothesis that these pathological changes contribute
to tremor and disturbed balance, gait, and postural reflexes
cannot be excluded, and could be investigated in func-
tional imaging studies.13 Interestingly, the deep cerebellar
pathology was often more severe than the alpha-synuclein
pathology in most precerebellar structures.12
Although we could for the first time demonstrate
alpha-synuclein inclusion pathology within the cerebel-
lum in PD and DLB, the time point at which the aggre-
gation pathology manifests remains to be elucidated. As
the affection of the cerebellum has not been considered
in PD and DLB staging systems, a reinvestigation of
PD- and DLB-related neuropathology regarding cerebel-
lar and precerebellar structures in a larger patient cohort,
including early cases, would be warranted.
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